Guillermo Navarro

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

Óscar Fernández, Guillermo Izquierdo, Victoria Fernández et al. · PLoS ONE · 2018 · 158 citations · Full text

Medicine, Neurology, Surgery +16

Genotype and phenotype analysis of Friedreich's ataxia compound heterozygous patients

Mirna Castro, Javier Garcı́a-Planells, Eugènia Monrós et al. · Human Genetics · 2000 · 60 citations

Life Sciences, Genetics, Molecular Genetics +14

Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients

Guillermo Izquierdo, Santiago Angulo, J M García-Moreno et al. · Acta Neurologica Scandinavica · 2002 · 60 citations

Life Sciences, Immunology, Neurology +12

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study

Fátima Damas, María Dolores Páramo, Juan Luis Ruíz-Peña et al. · PLoS ONE · 2017 · 51 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Long‐term epidemiology of multiple sclerosis in the <scp>N</scp> orthern <scp>S</scp> eville <scp>D</scp> istrict

Guillermo Izquierdo, Ana Venegas, Carmen Amalia Camacho Sanabria et al. · Acta Neurologica Scandinavica · 2015 · 35 citations · Full text

Medicine, Neurology, Clinical Epidemiology +13